NCT04330521 Impact of the Coronavirus (COVID-19) on Patients With Cancer
| NCT ID | NCT04330521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2020-04-08 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2020-04-08 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand the impact of COVID-19 on patients with cancer through a survey.
Eligibility Criteria
Inclusion Criteria: 1. The patients must be 18 years or older. 2. Patients who opt in to complete the survey. 3. Patients must have the capacity to verbally consent for the interview. Exclusion Criteria: 1.Patients who under the age of 18 years old.
Frequently Asked Questions
Who can join the NCT04330521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04330521 currently recruiting?
Yes, NCT04330521 is actively recruiting participants. Visit ClinicalTrials.gov or contact Stanford University to inquire about joining.
Where is the NCT04330521 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT04330521 clinical trial?
NCT04330521 is sponsored by Stanford University. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.